Mild clobetasol propionate cream regimen (10 to 30 g/day) showed no clear difference in mortality at 1 year compared with standard clobetasol propionate cream regimen (40 g/day) (low certainty).
The review found no eligible studies for this question.
Mild clobetasol propionate cream regimen (10 to 30 g/day) showed no clear difference in adverse events at 1 year compared with standard clobetasol propionate cream regimen (40 g/day) (low certainty).
Doxycycline leads to lower disease control at 6 weeks (unadjusted raw data) compared with prednisolone (high certainty).
It is very uncertain whether neoadjuvant treatment changes overall survival (OS), measured by the number of deaths over time… compared with no neoadjuvant treatment (very low certainty).
The review found no eligible studies for this question.
It is very uncertain whether neoadjuvant immunotherapy (talimogene laherparepvec) changes overall survival (OS), measured by the number of deaths over time, compared with no neoadjuvant treatment (very low certainty).
It is very uncertain whether neoadjuvant immunotherapy (talimogene laherparepvec) changes adverse Events, compared with no neoadjuvant treatment (very low certainty).
It is very uncertain whether neoadjuvant immunotherapy (talimogene laherparepvec) changes time to recurrence (TTR), measured by the number of disease… compared with no neoadjuvant treatment (very low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Neoadjuvant immunotherapy (combined ipilimumab and nivolumab) showed no clear difference in adverse events, compared with adjuvant immunotherapy (combined ipilimumab and nivolumab) (low certainty).
The review found no eligible studies for this question.
It is very uncertain whether neoadjuvant treatment changes adverse events, compared with no neoadjuvant treatment (very low certainty).
The review found no eligible studies for this question.
It is very uncertain whether neoadjuvant immunotherapy (combined ipilimumab and nivolumab) changes adverse events, compared with neoadjuvant immunotherapy (nivolumab) (very low certainty).
It is very uncertain whether neoadjuvant immunotherapy (combined ipilimumab and nivolumab) changes overall response rate (ORR), compared with neoadjuvant immunotherapy (nivolumab) (very low certainty).